Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2020 April;72(2) > Minerva Urologica e Nefrologica 2020 April;72(2):115-22

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Urologica e Nefrologica 2020 April;72(2):115-22

DOI: 10.23736/S0393-2249.18.03212-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Small cell carcinoma of the upper urinary tract and factors associated with progress survival: a systematic review and pooled analysis

Ning JIANG 1, 2, Dawei TIAN 1, Zhonghua SHEN 3, Peikang WU 1, 2, Yuwei HOU 4, Linguo XIE 1, Yuzhu LI 1, 2, Xiang ZHANG 1, Xiaogang TANG 1, Hailong HU 1, 2, Qiong PEI 3, Changli WU 1, 2

1 Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China; 2 Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, China; 3 Department of Urology, Tangshan Gongren Hospital, Tangshan, China; 4 Department of Magnetic Resonance, Tangshan Gongren Hospital, Tangshan, China



INTRODUCTION: Little is known about small cell carcinoma of the upper urinary tract (UUT-SCC), the aim of this study is to identify the risk factors in relation to survival of patients with UUT-SCC.
EVIDENCE ACQUISITION: Literature search on UUT-SCC was performed in databases including MEDLINE, EMBASE, Wangfang, and CNKI. Studies were eligible for inclusion if outcomes of patients with histopathologically confirmed UUT-SCC were reported. The relevant data on clinic, pathology, and therapy were collected. Progress survival was evaluated using the Cox regression model with the robust sandwich estimates of the covariance matrix.
EVIDENCE SYNTHESIS: There were 55 eligible publications identified, contributing 76 patients in total. The median of overall survival (OS) was 14 months. In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with OS (pT3-pT4 versus pT1-pT2, HR=3.228, P=0.005; other chemotherapies versus platinum-based, HR=6.249, P=0.035). The median of cancer-specific survival (CSS) was 15 months. In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with CCS (pT3-pT4 versus pT1-pT2, HR=3.332, P=0.004; non-platinum based versus platinum-based, HR=7.784, P=0.025).
CONCLUSIONS: In multivariable analyses, no variables were associated with OS and CSS. UUT-SCC is a rare tumor characterized by an aggressive clinical course. Pathological stage and platinum-based chemotherapy regimen are the most important factors related to OS and CSS.


KEY WORDS: Small cell carcinoma; Urinary tract; Survival rate

top of page